(22S,23R)-4,5-didehydro-5,6-dihydro-17,23-epoxyveratraman-3,11-dione (469-60-3)

Identification
Name:	(22S,23R)-4,5-didehydro-5,6-dihydro-17,23-epoxyveratraman-3,11-dione
Synonyms:	(17beta,23R)-4,5-didehydro-5,6-dihydro-17,23-epoxyveratraman-3,11-dione;(22S,23R)-4,5-Didehydro-5,6-dihydro-17,23-epoxyveratraman-3,11-dione
CAS:	469-60-3
Molecular Formula:	C₂₇H₃₇NO₃
Molecular Weight:	423.5876
InChI:	InChI=1/C27H37NO3/c1-14-11-21-24(28-13-14)16(3)27(31-21)10-8-19-20-6-5-17-12-18(29)7-9-26(17,4)23(20)25(30)22(19)15(27)2/h12,14,16,19-21,23-24,28H,5-11,13H2,1-4H3/t14-,16+,19-,20-,21+,23+,24-,26-,27-/m0/s1
Molecular Structure:
Properties
Flash Point:	314.6°C
Boiling Point:	596.6°C at 760 mmHg
Density:	1.18g/cm³
Refractive index:	1.584
Flash Point:	314.6°C
Safety Data

Other Product

(3beta,5alpha,12beta,13beta,22S,23R)-3-hydroxy-5,6,12,13-tetrahydro-17,23-epoxyveratraman-11-one
(8xi,9xi,10xi,14xi,20xi,22S,23R,25xi)-3-hydroxy-17,23-epoxyveratraman-11-one acetate (1:1)
24-Norchol-5-en-18-al,3-[[2-O-[6-deoxy-4-O-(4-hydroxybenzoyl)-a-L-mannopyranosyl]-b-D-glucopyranosyl]oxy]-16,23-epoxy-23-hydroxy-22-(2-methyl-1-propen-1-yl)-,(3b,16b,22S,23R)-
(22S,23R,25R)-23-Bromo-5α-spirostane
1/C17H22N6/c1-2-8-19-13-11-14(23-10-9-18-12-23)20-16-15(13)21-17(22-16)6-4-3-5-7-17/h9-12,19H,2-8H2,1H
1/C26H18O2/c1-17-16-23-21-9-5-3-7-19(21)11-13-25(23)28-26(17)15-14-22-20-8-4-2-6-18(20)10-12-24(22)27-26/h2-16H,1H
1/C19H15ClN2O2S/c1-11-19(23)24-17-18(25-11)22(2)15-9-8-13(20)10-14(15)16(21-17)12-6-4-3-5-7-12/h3-11H,1-2H
(20R,22S,23R,24S)-6-(ethylenedioxy)-20,22-dihydroxy-2α,3α-(isopropylidenedioxy)-23-(methoxymethoxy)-5α-ergostane
(20R,22S,23R,24R)-6-(ethylenedioxy)-2α,3α-(isopropylidenedioxy)-23-(methoxymethoxy)-20,22,28-trihydroxy-5α-ergostane
1/C22H28O6/c1-23-17-11-21(27-5)19(25-3)9-15(17)13-7-8-14(13)16-10-20(26-4)22(28-6)12-18(16)24-2/h9-14H,7-8H2,1-6H3/t13-,14
1/C18H19NO4/c1-22-15-8-11-10(7-13(15)20)5-12-16-9(3-4-19-12)6-14(21)18(23-2)17(11)16/h6-8,12,19-21H,3-5H2,1-2H
1/C16H15FN2O3S/c1-23(21,22)19-14-5-3-2-4-13(14)18-16(20)10-15(19)11-6-8-12(17)9-7-11/h2-9,15H,10H2,1H3,(H,18,20
b-D-Glucopyranoside, (3b,9b,10a,22S,23R,24R)-22,23,24,25-tetrahydroxy-9-methyl-19-norlanost-5-en-3-yl O-b-D-glucopyranosyl-(1®6)-O-[b-D-xylopyranosyl-(1®4)]-
Morphinan-6-ol, 8,14-didehydro-4, 5-epoxy-3-methoxy-17-methyl-, hydrobromide, (5.alpha.,6.alpha.)-
(20R,22S,23R,24S)-6-(ethylenedioxy)-20-hydroxy-2α,3α-(isopropylidenedioxy)-23-(methoxymethoxy)-5α-ergostano-28,22-lactone
(20R,22S,23R,24R)-6-(ethylenedioxy)-20,22-dihydroxy-2α,3α-(isopropylidenedioxy)-23-(methoxymethoxy)-28-[(methylsulfonyl)oxy]-5α-ergostane
(20R,22S,23R,24S)-22-acetoxy-6-(ethylenedioxy)-20-hydroxy-2α,3α-(isopropylidenedioxy)-23-(methoxymethoxy)-5α-ergostane
4-Hexenoic acid,2-hydroxy-6-[(1S,4E,6E,9R,11R,12S,13S,14Z,16E,19E,21R,23R,24R)-11-hydroxy-24-(hydroxymethyl)-12,15,24-trimethyl-3-oxo-2,22,26-trioxatricyclo[19.3.1.19,13]hexacosa-4,6,14,16,19-pentaen-23-yl]-,5-methyl-2-methylenehexyl ester, (2S,4Z)-
b-D-Glucopyranoside, (3b,9b,10a,22S,23R,24R)-22,23,24,25-tetrahydroxy-9-methyl-19-norlanost-5-en-3-yl
Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-, phosphate (1:1) (salt), mixt. with 2-(acetyloxy)benzoic acid, 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione and 5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione